Cook Medical leads Zenflow's $52M round and takes over U.S. sales of its prostate implant
Cook Medical led Zenflow's oversubscribed $52 million Series D and will be the exclusive U.S. distributor of the Zenflow Spring, an in-office implant for enlarged prostate that the FDA approved in December 2025.

- Amount
- $52M
- Type
- Series D
- Company
- Zenflow
- Lead investor
- Cook Medical
- Sector
- Medtech
- Announced
- Oct. 5, 2026
Cook Medical invested in Zenflow before its prostate implant had Food and Drug Administration approval. Now that the device is approved, Cook is putting in more money and taking over the selling.
Zenflow Inc. said Oct. 5 that Cook led its oversubscribed $52 million Series D round and signed on as the exclusive U.S. distributor of the Zenflow Spring System, an implant the South San Francisco, Calif., company says treats benign prostatic hyperplasia (BPH), or enlarged prostate, in a doctor's office.
Why it matters: The agreement turns Zenflow's lead strategic investor into its route to market. Zenflow will reach U.S. urologists through Cook, which pointed in its own announcement to its commercial infrastructure and its relationships with those physicians.
ClavystBio joined the round as a new investor, alongside existing backers Invus Opportunities, F-Prime and Medtech Venture Partners, among others. HSBC Bank USA and Trinity Capital added venture debt, Zenflow said. Neither company disclosed the size of the debt facility, a valuation or the financial terms of the distribution deal.
From backer to distributor
Cook's first check came in November 2024, when it led a $24 million Series C. Zenflow said then that the money would pay for its premarket approval application to the FDA and preparation for a commercial launch.
The FDA approved the Spring System in December 2025 through the premarket approval pathway, the agency's route for the highest-risk devices, Zenflow said. In September 2026, the company announced that four U.S. centers had completed procedures with the implant. Proceeds from the Series D will go toward speeding up the commercial launch, Zenflow said.
"Our initial investment in Zenflow reflected our confidence in both the technology and the team," DJ Sirota, senior vice president of Cook Medical's MedSurg division, said in Cook's announcement. Cook, based in Bloomington, Ind., said the implant joins its line of prostate health products.
Andrew Cleeland, Zenflow's board chairman, said in Zenflow's release that joining Zenflow's operations to Cook's sales know-how would speed up the launch.
The device and the market
Zenflow describes the Spring System as a minimally invasive, in-office BPH treatment that comes in multiple sizes and can be fully reversed. Cook describes it as a nitinol implant placed in the urethra during an office procedure that, according to Cook, involves no incisions, no general anesthesia and no tissue removal. When it announced its 2024 investment, Cook described the device as a small spring-like coil that props the urethra open.
The companies are positioning the implant as what they call first-line interventional therapy: a device-based alternative to medication. Zenflow cited published estimates that BPH affects 32 million U.S. men over 60 and 79 million men globally.
"Cook Medical's deep relationships within urology and proven commercialization capabilities make them the ideal partner," Shreya Mehta, Zenflow's chief executive, said.
What to watch
The open question is timing. Cook said details on commercial availability through its network and on rollout timelines would come later. The companies have not said how many centers are now offering the procedure beyond the four Zenflow announced in September, or how the device will be priced.



